The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology

被引：54

作者：

Apostolova, Liana G. ^{[1
,2
,3
]}

Aisen, Paul ^{[4
]}

Eloyan, Ani ^{[5
]}

Fagan, Anne ^{[6
]}

Fargo, Keith N. ^{[7
]}

Foroud, Tatiana ^{[3
]}

Gatsonis, Constantine ^{[5
]}

Grinberg, Lea T. ^{[8
,9
]}

Jack, Clifford R., Jr. ^{[10
]}

Kramer, Joel ^{[9
]}

Koeppe, Robert ^{[11
]}

Kukull, Walter A. ^{[12
]}

Murray, Melissa E. ^{[13
]}

Nudelman, Kelly ^{[3
]}

Rumbaugh, Malia ^{[3
]}

Toga, Arthur ^{[14
]}

Vemuri, Prashanthi ^{[10
]}

Trullinger, Amy ^{[15
]}

Iaccarino, Leonardo ^{[9
]}

Day, Gregory S. ^{[16
]}

Graff-Radford, Neill R. ^{[16
]}

Honig, Lawrence S. ^{[17
,18
]}

Jones, David T. ^{[10
,19
]}

Masdeu, Joseph ^{[20
]}

Mendez, Mario ^{[21
]}

Musiek, Erik ^{[6
]}

Onyike, Chiadi U. ^{[22
]}

Rogalski, Emily ^{[23
]}

Salloway, Steve ^{[24
]}

Wolk, David A. ^{[25
]}

Wingo, Thomas S. ^{[26
]}

Carrillo, Maria C. ^{[27
]}

Dickerson, Bradford C. ^{[28
,29
]}

Rabinovici, Gil D. ^{[9
]}

机构：

[1] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN 46202 USA

[2] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Ctr Neuroimaging, Indianapolis, IN 46202 USA

[3] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA

[4] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego, CA USA

[5] Brown Univ, Dept Biostat, Ctr Stat Sci, Providence, RI 02912 USA

[6] Washington Univ, Dept Neurol, St Louis, MO 63110 USA

[7] Charcot Marie Tooth Res Fdn, Naperville, IL USA

[8] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA

[9] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[10] Mayo Clin, Dept Radiol, Rochester, MN USA

[11] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA

[12] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[13] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA

[14] Keck Sch Med USC, USC Stevens Neuroimaging & Informat Inst, Lab Neuro Imaging, Los Angeles, CA USA

[15] Indiana Univ, Sch Med Indianapolis, Indiana Clin & Translat Sci Inst, Indianapolis, IN 46204 USA

[16] Mayo Clin, Dept Neurol, Jacksonville, FL USA

[17] Columbia Univ, Irving Med Ctr, Taub Inst, New York, NY USA

[18] Columbia Univ, Dept Neurol, Irving Med Ctr, New York, NY USA

[19] Mayo Clin, Dept Neurol, Rochester, MN USA

[20] Houston Methodist & Weill Cornell Med, Nantz Natl Alzheimer Ctr, Houston, TX USA

[21] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA

[22] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA

[23] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Mesulam Ctr Cognit Neurol & Alzheimers Dis, Chicago, IL 60611 USA

[24] Brown Univ, Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA

[25] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA

[26] Emory Univ, Sch Med, Dept Neurol & Human Genet, Atlanta, GA USA

[27] Alzheimers Assoc, Med & Sci Relat Div, Chicago, IL USA

[28] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA

[29] Harvard Med Sch, Boston, MA 02115 USA

来源：

ALZHEIMERS & DEMENTIA | 2021年 / 17卷 / 12期

关键词：

Alzheimer' s disease; early‐ onset; EOAD; LEADS; YOAD; young onset; NATIONAL INSTITUTE; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; GLUCOSE-METABOLISM; DEMENTIA SEVERITY; SENILE-DEMENTIA; AGE; PATTERNS; ATROPHY; PRESENILE;

D O I：

10.1002/alz.12350

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Patients with early-onset Alzheimer's disease (EOAD) are commonly excluded from large-scale observational and therapeutic studies due to their young age, atypical presentation, or absence of pathogenic mutations. The goals of the Longitudinal EOAD Study (LEADS) are to (1) define the clinical, imaging, and fluid biomarker characteristics of EOAD; (2) develop sensitive cognitive and biomarker measures for future clinical and research use; and (3) establish a trial-ready network. LEADS will follow 400 amyloid beta (A beta)-positive EOAD, 200 A beta-negative EOnonAD that meet National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) or AD dementia, and 100 age-matched controls. Participants will undergo clinical and cognitive assessments, magnetic resonance imaging (MRI), [F-18]Florbetaben and [F-18]Flortaucipir positron emission tomography (PET), lumbar puncture, and blood draw for DNA, RNA, plasma, serum and peripheral blood mononuclear cells, and post-mortem assessment. To develop more effective AD treatments, scientists need to understand the genetic, biological, and clinical processes involved in EOAD. LEADS will develop a public resource that will enable future planning and implementation of EOAD clinical trials.

引用

页码：2043 / 2055

页数：13

共 88 条

[31] NEOCORTICAL MORPHOMETRY, LESION COUNTS, AND CHOLINE-ACETYLTRANSFERASE LEVELS IN THE AGE SPECTRUM OF ALZHEIMERS-DISEASE [J].